Endovasc Announces Early Closure of Patient Recruitment for Liprostin Clinical Trial MONTGOMERY, Texas, April 1, 2004 (PRIMEZONE) -- Endovasc Inc. (OTCBB:EVSC), a drug development company that pioneers new cardiovascular and metabolic drug therapies, announced today the completion of...

Endovasc Provides Status Report on its $200 Million Case Against Alleged Stock Manipulators MONTGOMERY, Texas , Feb. 12, 2004 (PRIMEZONE) -- Endovasc Inc. (OTCBB:EVSC), a drug development company that pioneers new cardiovascular and metabolic drug therapies, announced today an update on the...

Two Clinical Sites in Mexico City Join Endovasc's Liprostin Phase II Trial MONTGOMERY, Texas, Jan. 28, 2004 (PRIMEZONE) -- Endovasc Inc. (OTCBB:EVSC), a drug development company that pioneers new cardiovascular and metabolic drug therapies, announced today that...

Endovasc Opens Four Sites in Moscow to Participate in Phase II Clinical Trial to Treat Patients Suffering from Peripheral Vascular Disease MONTGOMERY, Texas, Jan. 22, 2004 (PRIMEZONE) -- Endovasc Inc. (OTCBB:EVSC), a drug development company that pioneers new cardiovascular and metabolic drug therapies, is pleased to announce that...